Iovance Biotherapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDIovance Biotherapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 89), indicating clear outperformance against the broad market. Earnings growth of 47% provides fundamental context to the price action. Investors should exercise caution due to high volatility (102% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.04 | +0.38% | ABOVE |
| 50 SMA | $3.78 | +7.38% | ABOVE |
| 100 SMA | $3.62 | +12.18% | ABOVE |
| 150 SMA | $3.23 | +25.53% | ABOVE |
| 200 SMA | $2.98 | +36.34% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IOVA in an uptrend right now?
IOVA has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, IOVA is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is IOVA overbought or oversold?
IOVA's RSI (14) is 50. The stock is in neutral territory, neither overbought nor oversold.
Is IOVA outperforming the market?
IOVA has a Relative Strength (RS) Rating of 89 out of 99. Yes, IOVA is a market leader, outperforming 89% of all stocks over the past 12 months.
Where is IOVA in its 52-week range?
IOVA is trading at $4.06, which is 72% of its 52-week high ($5.63) and 60% above its 52-week low ($1.66).
How volatile is IOVA?
IOVA has a Beta of 1.74 and 52-week volatility of 102%. It's more volatile than the S&P 500 - expect bigger swings.